Recently, drugs combining NEP inhibition with angiotensin II receptor inhibition, named ARNi, have been introduced in the management of patients with HF, in order to maintain high levels of circulating NPs, as discussed in detail below [61,62]. This evidence concerns the gene MME and hydrops fetalis.